Reliance submits proposal for potential COVID drug


PTI, Jun 3, 2021, 4:58 PM IST

New Delhi: Reliance Industries Ltd”s R&D arm has proposed the use of Niclosamide – the drug used to treat tapeworm infestation – for treating COVID-19 patients.

Niclosamide, a drug on the World Health Organisation’s list of essential medicines, has been used to treat tapeworm infestation for more than 50 years. The oral antiviral drug was also used to treat patients during the SARS outbreak of 2003-04.

“The company submitted a proposal for the application of Niclosamide as a potential drug against COVID-19,” the firm’s latest annual report said.

The drug regulator will now evaluate the proposal for public use.

The company however did not say if it plans to manufacture the drug or would use it to treat COVID patients at hospitals run by the group.

The Indian government has already given clearance for the Phase 2 clinical trials of Niclosamide in COVID-19 treatment in adult patients.

The Reliance R&D (research and development) team is also working with various Council of Scientific & Industrial Research (CSIR) laboratories to certify Nexar polymer, which has been found to be effective in destroying the lipid layer of various viruses and bacteria.

Leveraging its intellectual capital to help the nation tackle the COVID-19 crisis, Reliance has developed novel cost-effective diagnostic kits called ”R-Green” and ”R-Green Pro” for COVID-19 detection. Both kits have received approval from the Indian Council of Medical Research (ICMR).

The company has also designed a process to produce sanitisers aligned with World Health Organization (WHO) specifications at 20 per cent of the market rate.

“Reliance is working to address insufficient ventilator supply in emergency rooms across hospitals in India by deploying a concept developed in Italy, which enables CPAP machine with a 3D-printed charlotte valve and special snorkelling mask,” the report said.

Seeing a significant rise in demand for onsite oxygen as the pandemic raged, Reliance has started working on a value-engineered robust design for oxygen generators capable of producing 5-7 litres of oxygen per minute with a purity of 90-95 per cent.

“Reliance has more than 900 researchers and scientists from world’s top institutes working on developing next-gen technology solutions to solve some of the most pressing Indian and global challenges,” the annual report said.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

NEET Row: Bihar Police recover 6 post-dated cheques ‘issued for question paper facilitators’

Congress slams ruling govt for statues’ relocation within Parliament, calls it ‘unilateral’ move

‘Sweeping generalisation’: BJP counters Elon Musk over EVM remark

No need to teach about riots, demolition in schools; no attempts to saffronise textbooks: NCERT chief

Puttur: 2 killed after two cars collide head-on

ICC’s Big American Dream: Too many loose ends, over-dependence on Indian market

BJP to stage protests across Karnataka against fuel price hike

Related Articles More

Sitharaman to hold pre-budget meeting with industry chambers on Jun 20

Mcap of five of top-10 most valued firms jumps Rs 85,582 cr; LIC biggest gainer

Manipal Energy and Infratech Limited (MEIL) bags “India 5000 Awards”

Govt must ensure corporate takeovers are fair, monopolies are not created: Congress on Adani acquiring Penna Cements

Sensex, Nifty hit fresh lifetime highs on buying in blue-chips HDFC Bank, Reliance

MUST WATCH

Road Mishap

VEENA STORES MALLESHWARAM

Kapu

Darshan Arrest | Renukaswamy Case

Udupi accident


Latest Additions

Ton-up Smriti, spinners hand India massive 143-run win over South Africa in 1st ODI

Police seal Navi Mumbai meat shop for ‘hurting’ religious sentiments

NEET Row: Bihar Police recover 6 post-dated cheques ‘issued for question paper facilitators’

Fresh political slugfest over EVM tampering claims; Defamation notice issued to newspaper by poll body

Limbs of newborn found in Goa, bitten by animals; FIR registered

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.